# Sermorelin vs Ipamorelin: GHRH Analog vs Ghrelin-Receptor Secretagogue > Sermorelin vs ipamorelin, reviewed: sermorelin is a GHRH analog acting on the GHRH receptor; ipamorelin is a GHRP acting on the ghrelin/GHS receptor. Two mechanisms, compared from the literature. Two growth-hormone secretagogues, two different receptors — and how sermorelin also sits against tesamorelin and CJC-1295, read from the literature. ## Start here The short answer on **sermorelin vs ipamorelin**: both tell the body to make more of its own growth hormone, but they push different buttons. Sermorelin is a GHRH analog — a copy of the brain's natural "make growth hormone" signal — and it works on the GHRH receptor. Ipamorelin is a different class (a growth-hormone-releasing peptide, or GHRP) that works on the ghrelin receptor, the same one the "hunger hormone" uses. Same goal, two doors into the pituitary. This page lays out that difference, then compares sermorelin with two more molecules people ask about — tesamorelin and CJC-1295. ## Sermorelin vs ipamorelin: two receptors, one goal The core of **sermorelin vs ipamorelin** is the receptor. Sermorelin is a GHRH analog — the native GHRH(1-29) fragment — acting on the GHRH receptor on pituitary somatotrophs, signaling through cAMP / PKA to release GH [13]. Ipamorelin is a growth-hormone-releasing peptide (GHRP), a different secretagogue class that acts on the ghrelin / growth-hormone-secretagogue (GHS) receptor — a separate pathway entirely. The simplest way to hold the distinction is that they imitate two different natural signals. Sermorelin imitates GHRH, the hypothalamus's dedicated "release growth hormone" command. Ipamorelin imitates ghrelin, a hormone better known for hunger, which the body also uses as a second, independent lever on GH release. Two different natural messengers, two different receptors on the same gland — and that is why the two compounds are described as having distinct, even complementary, mechanisms rather than being substitutes for one another. Because they hit different receptors, the two are mechanistically distinct rather than interchangeable. Both ultimately prompt the pituitary to release its own GH, and both leave that release subject to physiologic feedback through somatostatin and IGF-1, but they enter the system through different front doors. Sermorelin's evidence base is the GHRH-receptor literature reviewed across this site — the pediatric height-velocity trials, the adult GH/IGF-1 reversal in older men, and the pharmacokinetic work [1][2][3]. Ipamorelin sits in the GHRP family, which this digest does not claim to characterize in depth beyond the receptor-class distinction, because its own controlled literature is outside the sermorelin record this site reviews. ## Sermorelin vs CJC-1295 Sermorelin and CJC-1295 share the GHRH receptor, but differ sharply in duration. Sermorelin is the short native GHRH(1-29) with a plasma half-life on the order of 10-12 minutes [3]. CJC-1295 builds on a D-Ala2 substitution — a tweak to one amino acid that resists enzymatic breakdown — and, in its DAC form, adds a Drug Affinity Complex: a small chemical group that latches onto serum albumin (an abundant blood protein) so the peptide rides along in circulation far longer than sermorelin's minutes [3]. The practical contrast is duration, not destination. Both molecules knock on the same door — the GHRH receptor — and both rely on the body's own pituitary to answer by releasing GH in pulses. What changes is how long the stimulus lingers: sermorelin is a brief tap, the DAC-modified analog a sustained press. That is the whole reason the longer-acting analogs exist; sermorelin's brevity is the property they were engineered to overcome [3]. Whether a brief, pulse-like stimulus or a prolonged one is preferable is a research question this digest does not resolve — it simply reports the pharmacokinetic difference. ## Sermorelin vs tesamorelin Sermorelin and tesamorelin are both GHRH analogs acting on the same receptor, but tesamorelin is a stabilized molecule with a more developed clinical record. Where sermorelin is the unmodified native GHRH(1-29) fragment that clears in minutes [3], tesamorelin carries a chemical modification that makes it more resistant to breakdown — the kind of stabilization the field pursued precisely because the native fragment is so short-lived. That extra durability tracks with a deeper evidence base. Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy — abnormal fat redistribution associated with HIV therapy — and it is the analog behind the clearest body-composition and cognition data in this class. A controlled trial reported a 7.4% reduction in percent body fat and a favorable cognition effect over 20 weeks, with IGF-1 rising 117% but staying within the physiologic range [6]. Sermorelin, by contrast, is the native fragment, formerly approved for pediatric GH deficiency and now compounded [1], with its strongest data in childhood growth and adult endocrine response rather than body composition. Same mechanism family; different stability, different approved scope, and a different depth of evidence — which is why findings from one should not be quietly assigned to the other, a line this digest keeps explicit. ## How does sermorelin compare to CJC-1295? Both act on the GHRH receptor, but sermorelin is the short native GHRH(1-29) with a ~10-12 minute half-life [3]; CJC-1295 uses a DAC albumin-binding modification (building on the D-Ala2 substitution) to act far longer [3]. The target is shared; the duration is the difference. Sermorelin's brevity is what motivated the stabilized analogs. ## Sermorelin vs ipamorelin They work through different receptors: sermorelin is a GHRH analog acting on the GHRH receptor, while ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor [13]. Both prompt the pituitary to release its own GH, but through distinct pathways, so they are mechanistically different rather than interchangeable. ## Sermorelin vs direct HGH Sermorelin acts upstream on the pituitary to stimulate the body's own pulsatile GH, leaving somatostatin/IGF-1 feedback intact [13]; injected HGH supplies the hormone directly and bypasses that feedback. An editorial argued the secretagogue route is more physiologic for adult-onset GH insufficiency than recombinant GH [4]. This digest reports that argument; it does not endorse either approach. --- A reviewer's reading desk for the Sermorelin record — the GHRH(1-29) pediatric height-velocity, half-life, and adult GH/IGF-1 figures loaded into one window and read straight from the published literature; no clinic behind the screen and nothing here sourced, dispensed, or sold.